<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Tumors of female reproductive system</journal-id><journal-title-group><journal-title xml:lang="en">Tumors of female reproductive system</journal-title><trans-title-group xml:lang="ru"><trans-title>Опухоли женской репродуктивной системы</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1994-4098</issn><issn publication-format="electronic">1999-8627</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">993</article-id><article-id pub-id-type="doi">10.17650/1994-4098-2022-18-3-24-28</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>MAMMOLOGY. ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>МАММОЛОГИЯ. ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">Long-term oncological outcomes of organ-sparing treatment of patients with early breast cancer aged 65 years and older who had no postoperative radiation therapy</article-title><trans-title-group xml:lang="ru"><trans-title>Отдаленные онкологические результаты органосохраняющего лечения без послеоперационной лучевой терапии у больных ранним раком молочной железы старше 65 лет</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ortabaeva</surname><given-names>D.  R.</given-names></name><name xml:lang="ru"><surname>Ортабаева</surname><given-names>Д. Р.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>3 2<sup>nd</sup> Botkinskiy Proezd, Moscow 125284</p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7141-2502</contrib-id><name-alternatives><name xml:lang="en"><surname>Zikiryakhodzhaev</surname><given-names>A. D. </given-names></name><name xml:lang="ru"><surname>Зикиряходжаев</surname><given-names>А. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>3 2<sup>nd</sup> Botkinskiy Proezd, Moscow 125284</p><p>Build. 2, 8 Trubetskaya St., Moscow 119991</p><p>8 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p><p><italic>119991 Москва, ул. Трубецкая, 8, стр. 2</italic></p><p><italic>117198 Москва, ул. Миклухо-Маклая, 8</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/><xref ref-type="aff" rid="aff3"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Rasskazova</surname><given-names>E. A.</given-names></name><name xml:lang="ru"><surname>Рассказова</surname><given-names>Е. А.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Elena Aleksandrovna Rasskazova </p><p>3 2<sup>nd</sup> Botkinskiy Proezd, Moscow 125284</p></bio><bio xml:lang="ru"><p>Елена Александровна Рассказова </p><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><email>rasskaz2@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Saribekyan</surname><given-names>E. K. </given-names></name><name xml:lang="ru"><surname>Сарибекян</surname><given-names>Э. К.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>3 2<sup>nd</sup> Botkinskiy Proezd, Moscow 125284</p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p></bio><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaprin</surname><given-names>A. D.</given-names></name><name xml:lang="ru"><surname>Каприн</surname><given-names>А. Д.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>3 2<sup>nd</sup> Botkinskiy Proezd, Moscow 125284</p><p>8 Miklukho-Maklaya St., Moscow 117198</p></bio><bio xml:lang="ru"><p><italic>125284 Москва, 2-й Боткинский проезд, 3</italic></p><p><italic>117198 Москва, ул. Миклухо-Маклая, 8</italic></p></bio><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">P.A. Hertzen Moscow Oncology Research Institute – branch of the National Medical Research Radiology Center, Ministry of Health  of Russia</institution></aff><aff><institution xml:lang="ru">Московский научно-исследовательский онкологический институт им. П. А. Герцена – филиал ФГБУ «Национальный медицинский исследовательский центр радиологии» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">I.M. Sechenov First Moscow State Medical University, Ministry of Health of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Первый Московский государственный медицинский университет им. И. М. Сеченова» Минздрава России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute of Medicine, Peoples’ Friendship University of Russia</institution></aff><aff><institution xml:lang="ru">ФГАОУ ВО «Российский университет дружбы народов»</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2022-12-02" publication-format="electronic"><day>02</day><month>12</month><year>2022</year></pub-date><volume>18</volume><issue>3</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>24</fpage><lpage>28</lpage><history><date date-type="received" iso-8601-date="2022-12-01"><day>01</day><month>12</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-12-01"><day>01</day><month>12</month><year>2022</year></date></history><permissions><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://ojrs.abvpress.ru/ojrs/article/view/993">https://ojrs.abvpress.ru/ojrs/article/view/993</self-uri><abstract xml:lang="en"><p>Postoperative radiation therapy after breast-conserving surgery is a standard method of treating breast cancer, but recently the issue of its de-escalation in patients older than 65 due to concomitant pathology, lower life expectancy and possible development of post-radiation complications has been discussed. The results of some foreign studies prove the absence of a statistically significant difference in relapse-free and overall survival in patients with early breast cancer older than 65 years with relatively favorable clinical and morphological characteristics without postoperative radiation therapy. We analyzed the long-term oncological results in patients with breast cancer older than 65 years after breast-conserving surgery without postoperative radiation therapy. The results of the study showed that postoperative radiation therapy in patients over 65 years of age with stage IA pT1N0M0 breast cancer of luminal immunophenotype A does not improve long-term oncological indicators. Thus, the exclusion of postoperative radiation therapy from the treatment plan of this group of patients is oncologically safe and economically justified.</p></abstract><trans-abstract xml:lang="ru"><p>Послеоперационная лучевая терапия после органосохраняющих операций является стандартным методом лечения рака молочной железы (РмЖ), однако в последнее время обсуждается вопрос о ее деэскалации у больных старше 65 лет в связи с сопутствующей патологией, меньшей ожидаемой продолжительностью жизни и возможным развитием постлучевых осложнений. Результаты некоторых зарубежных исследований доказывают отсутствие статистически значимой разницы в безрецидивной и общей выживаемости у больных ранним РмЖ старше 65 лет с относительно благоприятными клинико-морфологическими характеристиками без послеоперационной лучевой терапии. Нами проведен анализ отдаленных онкологических результатов у больных РмЖ старше 65 лет после органосохраняющего хирургического лечения без послеоперационной лучевой терапии. Результаты исследования показали, что проведение послеоперационной лучевой терапии у больных старше 65 лет при IA стадии pT1N0M0 РмЖ люминального иммунофенотипа а не улучшает отдаленные онкологические показатели. таким образом, исключение послеоперационной лучевой терапии из плана лечения данной группы больных является онкологически безопасным и экономически обоснованным.</p></trans-abstract><kwd-group xml:lang="en"><kwd>breast cancer</kwd><kwd>postoperative radiation therapy</kwd><kwd>breast cancer in patients older than 65</kwd><kwd>breast-conserving surgery</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>рак молочной железы</kwd><kwd>послеоперационная лучевая терапия</kwd><kwd>рак молочной железы у больных старше 65 лет</kwd><kwd>органосохраняющее лечение рака молочной железы</kwd></kwd-group><funding-group/></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><citation-alternatives><mixed-citation xml:lang="en">1. Fisher B., Anderson S., Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347(16):1233–41. DOI: 10.1056/NEJMoa022152</mixed-citation><mixed-citation xml:lang="ru">Fisher B., Anderson S., Bryant J. et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347(16):1233–41. DOI: 10.1056/NEJMoa022152</mixed-citation></citation-alternatives></ref><ref id="B2"><label>2.</label><citation-alternatives><mixed-citation xml:lang="en">2. Fyles A.W., McCready D.R., Manchul L.A. et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351(10):963–70. DOI: 10.1056/NEJMoa040595</mixed-citation><mixed-citation xml:lang="ru">Fyles A.W., McCready D.R., Manchul L.A. et al. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351(10):963–70. DOI: 10.1056/NEJMoa040595</mixed-citation></citation-alternatives></ref><ref id="B3"><label>3.</label><citation-alternatives><mixed-citation xml:lang="en">3. Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S., McGale P. et al. Effect of radiotherapy after breastconserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378(9804):1707–16. DOI: 10.1016/S0140-6736(11)61629-2</mixed-citation><mixed-citation xml:lang="ru">Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Darby S., McGale P. et al. Effect of radiotherapy after breastconserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378(9804):1707–16. DOI: 10.1016/S0140-6736(11)61629-2</mixed-citation></citation-alternatives></ref><ref id="B4"><label>4.</label><citation-alternatives><mixed-citation xml:lang="en">4. Whelan T.J., Olivotto I.A., Parulekar W.R. et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373(4):307–16.</mixed-citation><mixed-citation xml:lang="ru">Whelan T.J., Olivotto I.A., Parulekar W.R. et al. Regional nodal irradiation in early-stage breast cancer. N Engl J Med 2015;373(4):307–16.</mixed-citation></citation-alternatives></ref><ref id="B5"><label>5.</label><citation-alternatives><mixed-citation xml:lang="en">5. Hughes K.S., Schnaper L.A., Bellon J.R. et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31(19):2382–7. DOI: 10.1200/JCO.2012.45.2615</mixed-citation><mixed-citation xml:lang="ru">Hughes K.S., Schnaper L.A., Bellon J.R. et al. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol 2013;31(19):2382–7. DOI: 10.1200/JCO.2012.45.2615</mixed-citation></citation-alternatives></ref><ref id="B6"><label>6.</label><citation-alternatives><mixed-citation xml:lang="en">6. Hughes K.S., Schnaper L.A., Berry D. et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351(10):971–7. DOI: 10.1056/NEJMoa040587</mixed-citation><mixed-citation xml:lang="ru">Hughes K.S., Schnaper L.A., Berry D. et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351(10):971–7. DOI: 10.1056/NEJMoa040587</mixed-citation></citation-alternatives></ref><ref id="B7"><label>7.</label><citation-alternatives><mixed-citation xml:lang="en">7. Arvold N.D., Taghian A.G., Niemierko A. et al. Age, breast cancer subtype approximation, and local recurrence after breastconserving therapy. J Clin Oncol 2011;29(29):3885–91.</mixed-citation><mixed-citation xml:lang="ru">Arvold N.D., Taghian A.G., Niemierko A. et al. Age, breast cancer subtype approximation, and local recurrence after breastconserving therapy. J Clin Oncol 2011;29(29):3885–91.</mixed-citation></citation-alternatives></ref><ref id="B8"><label>8.</label><citation-alternatives><mixed-citation xml:lang="en">8. Miles R.C., Gullerud R.E., Lohse C.M. et al. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol 2012;19(4):1153–9.</mixed-citation><mixed-citation xml:lang="ru">Miles R.C., Gullerud R.E., Lohse C.M. et al. Local recurrence after breast-conserving surgery: multivariable analysis of risk factors and the impact of young age. Ann Surg Oncol 2012;19(4):1153–9.</mixed-citation></citation-alternatives></ref><ref id="B9"><label>9.</label><citation-alternatives><mixed-citation xml:lang="en">9. Canavan J., Truong P.T., Smith S.L. et al. Local recurrence in women with stage I breast cancer: declining rates over time in a large, population-based cohort. Int J Radiat Oncol Biol Phys 2014;88(1):80–6.</mixed-citation><mixed-citation xml:lang="ru">Canavan J., Truong P.T., Smith S.L. et al. Local recurrence in women with stage I breast cancer: declining rates over time in a large, population-based cohort. Int J Radiat Oncol Biol Phys 2014;88(1):80–6.</mixed-citation></citation-alternatives></ref><ref id="B10"><label>10.</label><citation-alternatives><mixed-citation xml:lang="en">10. Smith S.L., Truong P.T., Lu L. et al. Identification of patients at very low risk of local recurrence after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2014;89(3):556–62.</mixed-citation><mixed-citation xml:lang="ru">Smith S.L., Truong P.T., Lu L. et al. Identification of patients at very low risk of local recurrence after breast-conserving surgery. Int J Radiat Oncol Biol Phys 2014;89(3):556–62.</mixed-citation></citation-alternatives></ref><ref id="B11"><label>11.</label><citation-alternatives><mixed-citation xml:lang="en">11. Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747–52.</mixed-citation><mixed-citation xml:lang="ru">Perou C.M., Sorlie T., Eisen M.B. et al. Molecular portraits of human breast tumours. Nature 2000;406(6797):747–52.</mixed-citation></citation-alternatives></ref><ref id="B12"><label>12.</label><citation-alternatives><mixed-citation xml:lang="en">12. Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869–74. DOI: 10.1073/pnas.191367098</mixed-citation><mixed-citation xml:lang="ru">Sorlie T., Perou C.M., Tibshirani R. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001;98(19):10869–74. DOI: 10.1073/pnas.191367098</mixed-citation></citation-alternatives></ref><ref id="B13"><label>13.</label><citation-alternatives><mixed-citation xml:lang="en">13. Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418–23.</mixed-citation><mixed-citation xml:lang="ru">Sorlie T., Tibshirani R., Parker J. et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003;100(14):8418–23.</mixed-citation></citation-alternatives></ref><ref id="B14"><label>14.</label><citation-alternatives><mixed-citation xml:lang="en">14. Fan C., Oh D.S., Wessels L. et al. Concordance among geneexpression-based predictors for breast cancer. N Engl J Med 2006;355(6):560–9. DOI: 10.1093/annonc/mds080</mixed-citation><mixed-citation xml:lang="ru">Fan C., Oh D.S., Wessels L. et al. Concordance among geneexpression-based predictors for breast cancer. N Engl J Med 2006;355(6):560–9. DOI: 10.1093/annonc/mds080</mixed-citation></citation-alternatives></ref><ref id="B15"><label>15.</label><citation-alternatives><mixed-citation xml:lang="en">15. Nguyen P.L., Taghian A.G., Katz M.S. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol 2008;26(14):2373–8. DOI: 10.1200/JCO.2007.14.4287</mixed-citation><mixed-citation xml:lang="ru">Nguyen P.L., Taghian A.G., Katz M.S. et al. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breastconserving therapy. J Clin Oncol 2008;26(14):2373–8. DOI: 10.1200/JCO.2007.14.4287</mixed-citation></citation-alternatives></ref><ref id="B16"><label>16.</label><citation-alternatives><mixed-citation xml:lang="en">16. Voduc K.D., Cheang M.C., Tyldesley S. et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28(10):1684–91. DOI: 10.1200/JCO.2009.24.9284</mixed-citation><mixed-citation xml:lang="ru">Voduc K.D., Cheang M.C., Tyldesley S. et al. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010;28(10):1684–91. DOI: 10.1200/JCO.2009.24.9284</mixed-citation></citation-alternatives></ref></ref-list></back></article>
